NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
NervGen Pharma priced a US$60 million public offering of 24 million common shares and accompanying warrants at US$2.50 per share. The company intends to use the net proceeds to advance its lead candidate NVG-291 through clinical studies and for general corporate purposes.
Key figures
- Deal Value Usd
- 60000000
- Offering Price
- 2.5
- Shares Offered
- 24000000
- Warrants offered
- 24000000
- Warrant exercise price
- 3.68
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.